The Gilead Sciences Acquisition of Arcellx reached its successful conclusion today, marking a transformative milestone for the biopharmaceutical giant’s oncology division. By folding Arcellx into its wholly-owned subsidiary, Kite, Gilead has secured full global rights to anitocabtagene autoleucel (anito-cel), a next-generation CAR T-cell therapy currently under FDA review for the treatment of relapsed or refractory multiple myeloma.
Strategic Value of the Gilead Sciences Acquisition of Arcellx
This $7.8 billion transaction reflects Gilead’s commitment to becoming a leader in cell therapy. Under the terms of the deal, Gilead paid $115.00 per share in cash, plus a contingent value right (CVR) of $5.00 per share, which is tied to achieving $6 billion in cumulative net sales by 2029.
By bringing the Gilead Sciences Acquisition of Arcellx to a close, the company eliminates future profit-sharing and royalty obligations previously established under their 2022 collaboration agreement. This move is expected to be accretive to earnings per share starting in 2028, following the anticipated 2026 market entry.
Clinical Excellence: Data from the iMMagine-1 Trial
A primary driver for the Gilead Sciences Acquisition of Arcellx was the exceptional clinical data presented at recent medical congresses, including the American Society of Hematology (ASH) Annual Meeting. The pivotal Phase 2 iMMagine-1 study demonstrated that anito-cel offers not only deep responses but also a safety profile that distinguishes it from existing BCMA-directed therapies.
Learn More: Gilead Acquire Tubulis in Landmark $5 Billion ADC Strategic Expansion
Efficacy Results for Anito-cel (iMMagine-1 Trial)
| Metric | Result (n=117) |
| Overall Response Rate (ORR) | 96% |
| Complete Response (sCR/CR) | 74% |
| MRD Negativity Rate (10⁻⁵) | 95% |
| 12-Month Progression-Free Survival | 82.1% |
| 12-Month Overall Survival | 94.0% |
FDA Announces AstraZeneca Truqap Prostate Cancer Approval for PTEN-Deficient Patients
US Food and Drug Administration has approved AstraZeneca's Truqap (capivasertib) combination therapy as the first and only targeted treatment for adult patients suffering from PTEN-deficient […]
Johnson & Johnson TALVEY Multiple Myeloma Treatment Shows Unprecedented Phase 3 MonumenTAL-3 Efficacy
Johnson & Johnson announced positive Phase 3 MonumenTAL-3 trial data demonstrating that a TALVEY-based bispecific combination significantly reduces the risk of progression or death in […]
Novo Nordisk IT Security Incident: Unauthorized System Access Detected in Denmark
Novo Nordisk A/S has confirmed an IT security breach involving unauthorized access to limited internal systems and data exfiltration. Core operations remain unaffected. […]
The Road to Commercialization in 2026
With the FDA having accepted the Biologics License Application (BLA) for anito-cel, the industry is closely watching the upcoming PDUFA date of December 23, 2026. The Gilead Sciences Acquisition of Arcellx ensures that Gilead’s industry-leading manufacturing infrastructure is fully prepared to scale production upon approval.
Anito-cel’s unique D-Domain binder technology allows for a high density of CAR expression on the cell surface, which researchers believe contributes to the lack of delayed neurotoxicities a side effect that has plagued other treatments in this class.
Last Modified:
